211 related articles for article (PubMed ID: 9818075)
1. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Brand R; Capadano M; Tempero M
Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
Buesa JM; Losa R; Fernández A; Sierra M; Esteban E; Díaz A; López-Pousa A; Fra J
Cancer; 2004 Nov; 101(10):2261-9. PubMed ID: 15484216
[TBL] [Abstract][Full Text] [Related]
5. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
[TBL] [Abstract][Full Text] [Related]
6. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
7. Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study.
Pollera CF; Ceribelli A; Crecco M; Calabresi F
Invest New Drugs; 1994; 12(2):111-9. PubMed ID: 7860227
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.
Maurel J; Zorrilla M; Puertolas T; Antón A; Herrero A; Artal A; Alonso V; Martinez-Trufero J; Puertas MM
Anticancer Drugs; 2001 Oct; 12(9):713-7. PubMed ID: 11593051
[TBL] [Abstract][Full Text] [Related]
9. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
Veltkamp SA; Beijnen JH; Schellens JH
Oncologist; 2008 Mar; 13(3):261-76. PubMed ID: 18378536
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680
[TBL] [Abstract][Full Text] [Related]
12. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF; Reitz J
Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804
[TBL] [Abstract][Full Text] [Related]
14. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
Schmid P; Schweigert M; Beinert T; Flath B; Sezer O; Possinger K
Invest New Drugs; 2005 Mar; 23(2):139-46. PubMed ID: 15744590
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of gemcitabine in advanced colorectal adenocarcinoma.
Moore DF; Pazdur R; Daugherty K; Tarassoff P; Abbruzzese JL
Invest New Drugs; 1992 Nov; 10(4):323-5. PubMed ID: 1487408
[TBL] [Abstract][Full Text] [Related]
16. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.
Pollera CF; Ceribelli A; Crecco M; Oliva C; Calabresi F
Invest New Drugs; 1997; 15(2):115-21. PubMed ID: 9220290
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
Schmid P; Akrivakis K; Flath B; Grosse Y; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Aug; 10(7):625-31. PubMed ID: 10507311
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report.
Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T
Lung Cancer; 1996 Feb; 14(1):135-44. PubMed ID: 8696717
[TBL] [Abstract][Full Text] [Related]
20. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
